MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida. Show more

Location: 1200 Brickell Avenue, Miami, FL, 32183, United States | Website: https://mirapharmaceuticals.com | Industry: Drug Manufacturers - General | Sector: Healthcare


Market Cap

26.51M

52 Wk Range

$0.73 - $2.56

Previous Close

$1.39

Open

$1.40

Volume

144,293

Day Range

$1.35 - $1.40

Enterprise Value

22.79M

Cash

730.5K

Avg Qtr Burn

-1.519M

Insider Ownership

22.04%

Institutional Own.

5.06%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.